Spravato
J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
July 24, 2024Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …
Janssen’s esketamine nasal spray secures CHMP recommendation in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder
December 11, 2020Medical Communications EMA, Europe, Spravato, depression
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has moved to recommend Janssen’s …
NICE knocks back Janssen’s Spravato nasal spray for the second time in treatment-resistant depression
September 3, 2020Sales and Marketing Janssen, Spravato, depression, pharma
NICE has opted to reject Janssen’s nasal spray Spravato (esketamine) for routine use on the NHS for treatment-resistant major depressive …
FDA expands approval for Janssen’s Spravato nasal spray to cover major depressive disorder with suicidal ideation
August 4, 2020Manufacturing and Production FDA Janssen, Spravato, depression
The FDA has moved to expand the existing approval of Janssen’s Spravato (esketamine) CIII nasal spray to include treatment of symptoms …
NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression
January 28, 2020Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression
Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …
New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression
May 21, 2019Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma
New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …
Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression
March 21, 2019Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs
The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …
Janssen’s party drug-based nasal spray becomes first new FDA-approved depression treatment in 30 years
March 6, 2019Research and Development, Sales and Marketing Janssen, Spravato, depression, esketamine, pharma
The field of depression therapy has seen its biggest leap forward in over three decades, the FDA approval of Janssen’s …
Janssen’s esketamine drug recommended by FDA panel for depression
February 13, 2019Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma
In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …
